Cochrane Abstracts
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Target of Rapamycin Inhibitors (TOR‐I; Sirolimus and Everolimus) for Primary Immunosuppression in Kidney Transplant Recipients." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439776/all/Target_of_rapamycin_inhibitors__TOR‐I. Accessed 07 June 2023.
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439776/all/Target_of_rapamycin_inhibitors__TOR‐I. Accessed June 7, 2023.
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/439776/all/Target_of_rapamycin_inhibitors__TOR‐I
Target of Rapamycin Inhibitors (TOR‐I; Sirolimus and Everolimus) for Primary Immunosuppression in Kidney Transplant Recipients [Internet]. In: Cochrane Abstracts. [cited 2023 June 07]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439776/all/Target_of_rapamycin_inhibitors__TOR‐I.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
ID - 439776
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439776/all/Target_of_rapamycin_inhibitors__TOR‐I
DB - Evidence Central
DP - Unbound Medicine
ER -
